ACE2 and COVID-19: The increased ACE-2 and decreased TMPRSS2 expressions might explain the lower impact of SARS-CoV-2 in patients with CF; however, our study contrasts with the present literature because our patients with CF and COVID-19 presented worse outcomes than those infected by other viruses.